6.
Kantrowitz J, Woods S, Petkova E, Cornblatt B, Corcoran C, Chen H
. D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial. Lancet Psychiatry. 2015; 2(5):403-412.
DOI: 10.1016/S2215-0366(15)00098-X.
View
7.
Emsley R
. Drugs in development for the treatment of schizophrenia. Expert Opin Investig Drugs. 2009; 18(8):1103-18.
DOI: 10.1517/13543780903066756.
View
8.
ODonnell B, Vohs J, Krishnan G, Rass O, Hetrick W, Morzorati S
. The auditory steady-state response (ASSR): a translational biomarker for schizophrenia. Suppl Clin Neurophysiol. 2013; 62:101-12.
PMC: 4959266.
DOI: 10.1016/b978-0-7020-5307-8.00006-5.
View
9.
Bialon M, Chocyk A, Majcher-Maslanka I, Zarnowska M, Michalski K, Antkiewicz-Michaluk L
. 1MeTIQ and olanzapine, despite their neurochemical impact, did not ameliorate performance in fear conditioning and social interaction tests in an MK-801 rat model of schizophrenia. Pharmacol Rep. 2021; 73(2):490-505.
PMC: 7994239.
DOI: 10.1007/s43440-020-00209-9.
View
10.
Grent-t-Jong T, Gross J, Goense J, Wibral M, Gajwani R, Gumley A
. Resting-state gamma-band power alterations in schizophrenia reveal E/I-balance abnormalities across illness-stages. Elife. 2018; 7.
PMC: 6160226.
DOI: 10.7554/eLife.37799.
View
11.
Tada M, Kirihara K, Koshiyama D, Nagai T, Fujiouka M, Usui K
. Alterations of auditory-evoked gamma oscillations are more pronounced than alterations of spontaneous power of gamma oscillation in early stages of schizophrenia. Transl Psychiatry. 2023; 13(1):218.
PMC: 10293250.
DOI: 10.1038/s41398-023-02511-5.
View
12.
Mace S, Taylor D
. Aripiprazole: dose-response relationship in schizophrenia and schizoaffective disorder. CNS Drugs. 2009; 23(9):773-80.
DOI: 10.2165/11310820-000000000-00000.
View
13.
Baune B
. Aripiprazole 2-month ready-to-use 960 mg (Ari 2MRTU): review of its possible role in schizophrenia therapy. Curr Med Res Opin. 2023; 40(1):87-96.
DOI: 10.1080/03007995.2023.2287612.
View
14.
Clifton N, Morisot N, Girardon S, Millan M, Loiseau F
. Enhancement of social novelty discrimination by positive allosteric modulators at metabotropic glutamate 5 receptors: adolescent administration prevents adult-onset deficits induced by neonatal treatment with phencyclidine. Psychopharmacology (Berl). 2012; 225(3):579-94.
DOI: 10.1007/s00213-012-2845-3.
View
15.
Owen M, Sawa A, Mortensen P
. Schizophrenia. Lancet. 2016; 388(10039):86-97.
PMC: 4940219.
DOI: 10.1016/S0140-6736(15)01121-6.
View
16.
Correll C, Schooler N
. Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment. Neuropsychiatr Dis Treat. 2020; 16:519-534.
PMC: 7041437.
DOI: 10.2147/NDT.S225643.
View
17.
Remington G, Foussias G, Fervaha G, Agid O, Takeuchi H, Lee J
. Treating Negative Symptoms in Schizophrenia: an Update. Curr Treat Options Psychiatry. 2016; 3:133-150.
PMC: 4908169.
DOI: 10.1007/s40501-016-0075-8.
View
18.
Koshiyama D, Miyakoshi M, Thomas M, Joshi Y, Molina J, Tanaka-Koshiyama K
. Unique contributions of sensory discrimination and gamma synchronization deficits to cognitive, clinical, and psychosocial functional impairments in schizophrenia. Schizophr Res. 2021; 228:280-287.
DOI: 10.1016/j.schres.2020.12.042.
View
19.
Hong L, Summerfelt A, McMahon R, Adami H, Francis G, Elliott A
. Evoked gamma band synchronization and the liability for schizophrenia. Schizophr Res. 2004; 70(2-3):293-302.
DOI: 10.1016/j.schres.2003.12.011.
View
20.
Hereta M, Kaminska K, Rogoz Z
. Co-treatment with antidepressants and aripiprazole reversed the MK-801-induced some negative symptoms of schizophrenia in rats. Pharmacol Rep. 2019; 71(5):768-773.
DOI: 10.1016/j.pharep.2019.04.007.
View